Status:
COMPLETED
Safety of RG2077 in Patients With Multiple Sclerosis
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Immune Tolerance Network (ITN)
Repligen Corporation
Conditions:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug...
Detailed Description
Effective treatment of autoimmune disorders is likely to arise not from improved immunosuppression, but from improved understanding of the normal mechanisms that generate and maintain self-tolerance. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate clinical events, or one clinical event and MRI consistent with demyelination plus a second MRI demonstrating new lesions
- Have declined all FDA approved therapies for MS
Exclusion
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00076934
Start Date
January 1 2003
End Date
February 1 2006
Last Update
March 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital/Harvard Medical School
Boston, Massachusetts, United States, 02115